Cyclacel, Daiichi Sankyo deal

The companies amended a 2003 deal granting Cyclacel exclusive, worldwide rights to Daiichi's sapacitabine ( CYC682). Under the amended deal, Daiichi waived its termination right under a provision that required Cyclacel to obtain regulatory approval for sapacitabine in at least one country by September 2011. Additionally, royalty payments to Daiichi from Cyclacel on future sales of sapacitabine were increased by 1.25-1.5% (see BioCentury, Dec. 8, 2003). ...